Discovery, Development, Inventions, and Patent Trends on Mobocertinib Succinate: The First-in-Class Oral Treatment for NSCLC with EGFR Exon 20 Insertions
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Discovery, Development, Inventions, and Patent Trends on Mobocertinib Succinate: The First-in-Class Oral Treatment for NSCLC with EGFR Exon 20 Insertions
Authors
Keywords
-
Journal
Biomedicines
Volume 9, Issue 12, Pages 1938
Publisher
MDPI AG
Online
2021-12-20
DOI
10.3390/biomedicines9121938
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Subtypes of EGFR and HER2 mutant metastatic NSCLC influence response to immune checkpoint inhibitors
- (2021) Sally CM. Lau et al. Clinical Lung Cancer
- Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2021) Hyuna Sung et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Response to standard therapies and comprehensive genomic analysis for patients with lung adenocarcinoma with EGFR exon 20 insertions
- (2021) Noura J. Choudhury et al. CLINICAL CANCER RESEARCH
- Synthetic molecules as DprE1 inhibitors: A patent review
- (2021) Mohd. Imran et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- Epidemiological and clinical burden of EGFR Exon 20 insertion in advanced non-small cell lung cancer: A systematic literature review
- (2021) Heather Burnett et al. PLoS One
- Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations From a Phase 1/2 Trial
- (2021) Gregory J. Riely et al. Cancer Discovery
- Mobocertinib (TAK-788): A Targeted Inhibitor of EGFR Exon 20 Insertion Mutants in Non-Small Cell Lung Cancer
- (2021) Francois Gonzalvez et al. Cancer Discovery
- Afatinib as First-Line Treatment in Asian Patients with EGFR Mutation-Positive NSCLC: A Narrative Review of Real-World Evidence
- (2021) Shun Lu et al. ADVANCES IN THERAPY
- Amivantamab: First Approval
- (2021) Yahiya Y. Syed DRUGS
- Osimertinib in EGFR-Mutated Lung Cancer: A Review of the Existing and Emerging Clinical Data
- (2021) Chung-Shien Lee et al. OncoTargets and Therapy
- Mobocertinib: A Potential Treatment for NSCLC with EGFR Exon 20 Insertions
- (2021) Jose M. Pacheco Cancer Discovery
- Effects of Itraconazole and Rifampin on the Pharmacokinetics of Mobocertinib (TAK‐788), an Oral Epidermal Growth Factor Receptor Inhibitor, in Healthy Volunteers
- (2021) Steven Zhang et al. Clinical Pharmacology in Drug Development
- Single‐Dose Pharmacokinetics and Tolerability of the Oral Epidermal Growth Factor Receptor Inhibitor Mobocertinib (TAK‐788) in Healthy Volunteers: Low‐Fat Meal Effect and Relative Bioavailability of 2 Capsule Products
- (2021) Steven Zhang et al. Clinical Pharmacology in Drug Development
- Trends in the development of remdesivir based inventions against COVID-19 and other disorders: A patent review
- (2021) Mohd. Imran et al. Journal of Infection and Public Health
- Innovations and Patent Trends in the Development of USFDA Approved Protein Kinase Inhibitors in the Last Two Decades
- (2021) Mohd. Imran et al. Pharmaceuticals
- Discovery, Development, and Patent Trends on Molnupiravir: A Prospective Oral Treatment for COVID-19
- (2021) Mohd. Imran et al. MOLECULES
- Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion–Positive Metastatic Non–Small Cell Lung Cancer
- (2021) Caicun Zhou et al. JAMA Oncology
- Anlotinib as a molecular targeted therapy for tumors (Review)
- (2020) Yi Gao et al. Oncology Letters
- EGFR exon 20 insertion mutations in non-small cell lung cancer
- (2020) Fenfang Wang et al. Translational Cancer Research
- The Effect of Advances in Lung-Cancer Treatment on Population Mortality
- (2020) Nadia Howlader et al. NEW ENGLAND JOURNAL OF MEDICINE
- Extensive functional evaluation of exon 20 insertion mutations of EGFR
- (2020) Takeshi Hirose et al. LUNG CANCER
- Non–Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment
- (2019) Narjust Duma et al. MAYO CLINIC PROCEEDINGS
- Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer harboring uncommon EGFR mutations: Focus on afatinib
- (2019) Ashiq Masood et al. SEMINARS IN ONCOLOGY
- Clinical evaluation of dacomitinib for the treatment of metastatic non-small cell lung cancer (NSCLC): current perspectives
- (2019) Daniele Lavacchi et al. Drug Design Development and Therapy
- Targeting EGFR in Lung Cancer: Current Standards and Developments
- (2018) Asunción Díaz-Serrano et al. DRUGS
- Recognising Lung Cancer in Primary Care
- (2018) Stephen H. Bradley et al. ADVANCES IN THERAPY
- EGFR exon 20 insertion in lung adenocarcinomas among Hispanics (geno1.2-CLICaP)
- (2018) Andrés F. Cardona et al. LUNG CANCER
- Risk factors for lung cancer worldwide
- (2016) Jyoti Malhotra et al. EUROPEAN RESPIRATORY JOURNAL
- Pharmaceutical salts: A summary on doses of salt formers from the Orange Book
- (2013) C. Saal et al. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
- EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications
- (2011) Hiroyuki Yasuda et al. LANCET ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation